Previous 10 | Next 10 |
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in th...
Kazia Therapeutics to Present at LD Micro Main Event PR Newswire SYDNEY , Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner , will ...
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference PR Newswire SYDNEY , Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce t...
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day PR Newswire SYDNEY , July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recogniz...
Kazia Therapeutics ([[KZIA]] +3.9%) provides an update on recent progress with its two pipeline assets, paxalisib and EVT801.The company's GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm.Paxalisib phase II study...
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs PR Newswire SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an upd...
Kazia Therapeutics ([[KZIA]] +1.5%) has entered a collaboration with Cornell University in the United States, to launch a phase II clinical study investigating the use of the company's paxalisib in combination with ketogenesis, for glioblastoma.This study will comprise two arms: The firs...
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma PR Newswire SYDNEY , June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an ...
Kazia Therapeutics (KZIA) announces that a mid-stage study of the company's primary CNS lymphoma treatment, paxalisib, has been initiated at Dana-Farber Cancer Institute, with the first patient enrolled to the study.Lymphoma is a cancer of white blood cells. It occurs in the lymphatic sy...
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient PR Newswire SYDNEY , June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to anno...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...